{"product_id":"stab-vrio-analysis","title":"Statera Biopharma, Inc. (STAB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Statera Biopharma, Inc. (STAB)'s market dominance starts here: this VRIO analysis cuts straight to the core, assessing whether its resources are truly Valuable, Rare, Inimitable, and Organized for lasting competitive advantage. The distilled summary in \u0026amp;O4\u0026amp; reveals the critical findings - read on immediately to see precisely where Statera Biopharma, Inc. (STAB) stands against its rivals.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 1. Advanced Immunomodulating Multi-component System (AIMS) Platform\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Statera Biopharma, Inc. (STAB) and trying to figure out if their core technology, the Advanced Immunomodulating Multi-component System (AIMS) Platform, is a durable asset. Honestly, the science behind a multi-component, pleiotropic approach to immune rebalancing is compelling, offering a path to differentiated therapies that single-target drugs often miss.\u003c\/p\u003e\n\u003cp\u003eThe platform is valuable because it provides a systematic way to discover and formulate drugs that target complex immune pathways. This isn't just another small molecule; it’s a proprietary methodology. Still, the financial reality right now is a major headwind to realizing that value.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on their current liquidity, which is the key constraint on Organization:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash \u0026amp; Cash Equivalents: \u003cstrong\u003e$506,098\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio: \u003cstrong\u003e0.05\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOperating Cash Flow (Last 12 Months): \u003cstrong\u003e-$12.09 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is that a current ratio of \u003cstrong\u003e0.05\u003c\/strong\u003e means they have only five cents in current assets for every dollar in current liabilities. If onboarding takes 14+ days longer than expected, solvency risk rises.\u003c\/p\u003e\n\n\u003cp\u003eAssessing the VRIO dimensions for the AIMS Platform gives us a clearer picture of its competitive standing:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePotential for economic value creation through differentiated therapies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eThe multi-component, pleiotropic approach is less common than standard single-target efforts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eThe underlying biology is known, but the proprietary algorithms and compound libraries create a barrier.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003eCurrent financial distress prevents effective exploitation of the platform's potential.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eBecause the Organization component scores a 'No' due to severe funding constraints - evidenced by only \u003cstrong\u003e$506,098\u003c\/strong\u003e in cash and a current ratio of \u003cstrong\u003e0.05\u003c\/strong\u003e - the competitive advantage remains only \u003cstrong\u003eTemporary\u003c\/strong\u003e. The platform has the DNA for a sustained advantage, but the firm cannot currently organize resources to capture that advantage effectively.\u003c\/p\u003e\n\u003cp\u003eFor STAB to move this from temporary to sustained, they must immediately address the capital structure. The platform itself is rare and valuable, but without the cash to run trials or secure partnerships, it’s just potential on paper.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 2. STAT-201 Lead Candidate (Pediatric Crohn's Disease)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eSTAT-201 Lead Candidate (Pediatric Crohn's Disease)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRepresents the most advanced asset, having completed an end-of-Phase 2 meeting with the FDA for a Phase 3 trial in pediatric Crohn's. Phase 2 study demonstrated proof of concept and safety.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 2 Remission Rate: \u003cstrong\u003e67%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePhase 2 Mucosal Healing Rate (Endoscopic): \u003cstrong\u003e43%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFDA Orphan Drug Designation: Granted for treatment of CD in pediatric patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo. Many companies target Crohn's, but a late-stage pediatric candidate is less common. Phase 3 trial protocol submission occurred on December 29, 2021, with Central IRB approval on February 15, 2022.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow. The clinical data and regulatory feedback are unique to Statera Biopharma, Inc. The Phase 3 trial was planned to enroll approximately \u003cstrong\u003e165 participants\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. The plan for Phase 3 exists, but execution is contingent on securing significant capital, which is a major hurdle given the company's financial performance.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (TTM)\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$91.83 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.69 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$1.91\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$12.09 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$12.19 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eCash \u0026amp; Cash Equivalents: \u003cstrong\u003e$506,098\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Debt: \u003cstrong\u003e$7.41 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Cash Position: \u003cstrong\u003e-$6.90 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. Value is high if Phase 3 succeeds, but the company's current state risks stalling development. Success in Phase 3 would validate STAT-201 as an immune modulator for restoring mucosal healing and intestinal barrier function as an adjunct to standard of care in moderate to severe Crohn's Disease.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 3. Intellectual Property (IP) Portfolio Covering AIMS and STAT Series\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a legal barrier to entry, protecting the novel compositions and their mechanisms of action from direct copying by competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. Specific patent claims on novel compounds and their use are inherently rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very Low. Patents offer the strongest defense against imitation, provided they are broad and well-maintained.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company has historically focused on securing this IP, which is a core function of a development-stage firm.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This is the bedrock of value for a pre-revenue biotech, assuming patents are robust.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Data Point\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Portfolio Count (Reported)\u003c\/td\u003e\n\u003ctd\u003eNumber of Medical Patents Associated (Patsnap Data)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\/Product Focus\u003c\/td\u003e\n\u003ctd\u003ePlatform Name\u003c\/td\u003e\n\u003ctd\u003eAIMS (Advanced Immunomodulating Multi-Component System)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Assets Mentioned\u003c\/td\u003e\n\u003ctd\u003eLead Candidate Indication\u003c\/td\u003e\n\u003ctd\u003eSTAT-201 for Crohn's Disease (Pediatric)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Assets Mentioned\u003c\/td\u003e\n\u003ctd\u003eTLR Agonists Platform Components\u003c\/td\u003e\n\u003ctd\u003eTLR4 and TLR9 antagonists, TLR5 agonists (Entolimod, Entalasta)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Transaction Value\u003c\/td\u003e\n\u003ctd\u003eEntolimod License Rights Sale to Tivic Health\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Related Expense (2021)\u003c\/td\u003e\n\u003ctd\u003eExpenses for IP Transfer (vs. $3,948,533 in 2020)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,306,307\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Assessment\u003c\/td\u003e\n\u003ctd\u003eInimitability Rating\u003c\/td\u003e\n\u003ctd\u003eVery Low\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eStatistical and Financial Data Relevant to IP\/R\u0026amp;D Investment:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet cash used for operating activities for the year ended December 31, 2021: \u003cstrong\u003e$5.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash used for operating activities for the year ended December 31, 2020: \u003cstrong\u003e$30.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) related headcount as of December 31, 2021: \u003cstrong\u003e12\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003eRevenue in the last 12 months: \u003cstrong\u003e$3.69 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLoss in the last 12 months: \u003cstrong\u003e-$91.83 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLoss per share in the last 12 months: \u003cstrong\u003e-$1.91\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating cash flow in the last 12 months: \u003cstrong\u003e-$12.09 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCapital expenditures in the last 12 months: \u003cstrong\u003e-$103,367\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReturn on Equity (ROE) in the last 12 months: \u003cstrong\u003e-286.94%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 4. Toll-like Receptor (TLR) Expertise (TLR2, 4, 5, 7, 9)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep, specialized scientific knowledge in modulating multiple TLRs, which is central to their immune rebalancing strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While TLR science is established, Statera Biopharma, Inc.'s specific application across this panel is specialized.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Scientific knowledge can be hired, but the institutional memory and specific compound data are not easily replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The expertise exists, but retaining key scientific personnel is difficult when total debt is \u003cstrong\u003e$7.41 million\u003c\/strong\u003e and cash is low.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a strong asset, but without capital, the knowledge risks becoming obsolete or walking out the door.\u003c\/p\u003e\n\u003cp\u003eThe institutional knowledge base is supported by specific assets and historical investment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform includes TLR agonists with \u003cstrong\u003eTLR4\u003c\/strong\u003e and \u003cstrong\u003eTLR9\u003c\/strong\u003e antagonists, and \u003cstrong\u003eTLR5\u003c\/strong\u003e agonists (Entolimod and Entalasta).\u003c\/li\u003e\n\u003cli\u003eThe TLR5 agonists, Entolimod and Entalasta, have been the subject of more than \u003cstrong\u003eforty\u003c\/strong\u003e animal and human trials.\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e$140 million\u003c\/strong\u003e of prior investment has been dedicated to the TLR5 agonist program.\u003c\/li\u003e\n\u003cli\u003eThe company has \u003cstrong\u003e46\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe breadth of the TLR expertise is reflected in the current and historical development pipeline:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTLR Target\/Modality\u003c\/td\u003e\n\u003ctd\u003eProduct Candidate\/Focus\u003c\/td\u003e\n\u003ctd\u003eDevelopment Stage\/Indication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTLR5 Agonist\u003c\/td\u003e\n\u003ctd\u003eEntolimod\u003c\/td\u003e\n\u003ctd\u003eClinical\/Hematology (Acute Radiation Syndrome)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTLR5 Agonist\u003c\/td\u003e\n\u003ctd\u003eEntalasta\u003c\/td\u003e\n\u003ctd\u003eClinical\/Potential Expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTLR Agonist\/Antagonist Platform\u003c\/td\u003e\n\u003ctd\u003eSTAT-201\u003c\/td\u003e\n\u003ctd\u003eClinical\/Crohn’s disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTLR Agonist\/Antagonist Platform\u003c\/td\u003e\n\u003ctd\u003eSTAT-300\u003c\/td\u003e\n\u003ctd\u003eClinical\/Inflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTLR Agonist\u003c\/td\u003e\n\u003ctd\u003eSTAT-600 therapies\u003c\/td\u003e\n\u003ctd\u003eRecombinant protein agonist of \u003cstrong\u003eTLR5\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial metrics highlight the organizational challenge in sustaining this expertise:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.41 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$506,098\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$6.90 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow (Last 12 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$12.09 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow (Last 12 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$12.19 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 5. STAT-205 Program (Acute\/Post-Acute COVID-19)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOffers a potential near-term market opportunity by addressing the high unmet need in post-acute COVID-19 syndrome (PACS) or 'long haulers.'\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRoughly \u003cstrong\u003e30%\u003c\/strong\u003e of all COVID-19 infections develop into long-haul syndrome.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. Several firms pursued COVID-19, but a specific immune-modulating approach for PACS is less crowded.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow. Any existing clinical data or IND clearance is company-specific.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePreliminary in vitro data demonstrated the ability to slow or halt the progression of SARS-CoV-2 in human lung cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. The program has an IND cleared, but the focus is likely shifting due to the dire financial situation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Investigational New Drug (IND) application has been cleared by the FDA.\u003c\/li\u003e\n\u003cli\u003eA Phase 1 pilot study protocol for Post-acute Sequalae of SARS-CoV-2 infection (PASC) was submitted to the FDA on March \u003cstrong\u003e02, 2022\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Phase 1 pilot study for PASC will enroll approximately \u003cstrong\u003e84\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. Success depends on rapid, low-cost clinical validation, which is tough with a current ratio of \u003cstrong\u003e0.05\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey Financial and Program Data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.05\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial Position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e506,098\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.41M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-6.90 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.69M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-91.83 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-1.91\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-12.09 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-12.19 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployee Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial Metrics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 6. Orphan Drug Designation for STAT-201\n\u003c\/h2\u003e\n\u003cp\u003eThe Orphan Drug Designation (ODD) for STAT-201 in pediatric Crohn's Disease (CD) represents a significant regulatory asset, supported by promising Phase 2 clinical data.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSTAT-201 Data Point\u003c\/th\u003e\n\u003cth\u003eContext\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan Drug Exclusivity (US)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStandard FDA Orphan Drug Exclusivity period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Remission Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eObserved in participants in the STAT-201 Phase 2 study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Mucosal Healing Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs measured by endoscopic assessment in the Phase 2 study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSerious Adverse Events (Phase 2)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported in the STAT-201 Phase 2 trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Status Milestone\u003c\/td\u003e\n\u003ctd\u003ePhase 3 Protocol Submission\u003c\/td\u003e\n\u003ctd\u003eSubmitted to the FDA in late 2021.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe designation provides significant regulatory incentives, including market exclusivity for \u003cstrong\u003e7 years\u003c\/strong\u003e post-approval in the US for the designated indication, which is expected to boost future commercial returns.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes. This designation is granted by the FDA only for rare pediatric diseases, which by definition limits the number of products receiving this status for a specific indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVery Low. This is a government-granted status that cannot be imitated; it must be earned through regulatory filings and meeting specific criteria.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes. The regulatory affairs team successfully secured this designation. Furthermore, the organization demonstrated capability by achieving a \u003cstrong\u003e67%\u003c\/strong\u003e remission rate in the Phase 2 trial.\u003c\/p\u003e\n\u003cp\u003eThe organizational competence is further evidenced by the progression to Phase 3 development, following an end-of-Phase 2 meeting with the FDA.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. This regulatory moat, based on the \u003cstrong\u003e7-year\u003c\/strong\u003e Orphan Drug Exclusivity, is a powerful, non-replicable asset for the STAT-201 indication.\u003c\/p\u003e\n\u003cp\u003eThe clinical data showing efficacy metrics such as:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRemission in \u003cstrong\u003e67%\u003c\/strong\u003e of participants.\u003c\/li\u003e\n\u003cli\u003eMucosal healing in \u003cstrong\u003e43%\u003c\/strong\u003e of participants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 7. STAT-401 Development Candidate (Pancreatic Cancer)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides diversification into oncology, targeting late-stage, non-resectable pancreatic cancer as an adjunct to standard of care.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe overall 5-year survival rate for Pancreatic Ductal Adenocarcinoma (PDAC) is approximately \u003cstrong\u003e5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eErlotinib plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, yielding a 'very modest survival benefit.'\u003c\/li\u003e\n\u003cli\u003eStatera planned to initiate a clinical trial in the \u003cstrong\u003efirst half of 2022\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. The target indication is high-need, and the injectable pentapeptide mechanism is specific.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow. The specific compound and its development pathway are proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow. This program appears less advanced than STAT-201, making it a secondary focus when capital is scarce.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSTAT-401 Indication\u003c\/td\u003e\n\u003ctd\u003eLate-stage, non-resectable Pancreatic Cancer\u003c\/td\u003e\n\u003ctd\u003eTarget Indication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSTAT-401 Compound Type\u003c\/td\u003e\n\u003ctd\u003eInjectable Pentapeptide\u003c\/td\u003e\n\u003ctd\u003eMechanism Specificity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDAC 5-Year Survival Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDisease Severity\/Need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares of Common Stock Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e51,141,362\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of August 31, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAggregate Market Value (Non-Affiliates)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48,863,444\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. It’s an option, but the company must prioritize to avoid spreading resources too thin.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStatera has clinical programs including STAT-201, Entolimod, STAT-401, and STAT-205.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 8. History of Securing Strategic Collaboration Payments\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates an ability to attract external interest and generate non-recurring revenue streams, like the one that contributed to the \u003cstrong\u003e$3.69 million\u003c\/strong\u003e TTM revenue. This revenue model is typical for a clinical-stage biopharma, but the scale of the associated loss is critical; the TTM net loss was \u003cstrong\u003e-$91.83 million\u003c\/strong\u003e on that revenue. The TTM Gross Profit Margin was approximately \u003cstrong\u003e70.19%\u003c\/strong\u003e ($2.59 million Gross Profit on $3.69 million revenue).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs can partner, but Statera Biopharma, Inc. has a track record of executing these deals, including a recent acquisition of rights by Tivic Health Systems and a royalty-bearing license agreement with Biostax Corp.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can seek partners, but the specific relationship history and deal terms are unique. The intellectual property involved in recent deals, such as the TLR5 agonist Entolimod and patents surrounding Low-dose Naltrexone (LDN) and Met-enkephalin (MENK), are specific assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The business development function has proven effective in the past, evidenced by securing agreements, though current focus is likely on survival given the distressed balance sheet, which included a current ratio of only \u003cstrong\u003e0.05\u003c\/strong\u003e and cash on hand of approximately \u003cstrong\u003e$506,098\u003c\/strong\u003e in the latest TTM period.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This capability is only valuable if the company can still attract partners despite its distressed balance sheet.\u003c\/p\u003e\n\u003cp\u003eThe historical reliance on, and recent execution of, strategic collaborations is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCollaboration\/Event\u003c\/th\u003e\n\u003cth\u003eDate\/Period Reference\u003c\/th\u003e\n\u003cth\u003eFinancial Implication\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Revenue Contribution\u003c\/td\u003e\n\u003ctd\u003eLatest TTM (leading to August 14, 2025 report)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.69 million\u003c\/strong\u003e (primarily non-recurring)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Comparison (2021 Annual)\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended December 31, 2021\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,487,036\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Trend Change (TTM vs. Prior)\u003c\/td\u003e\n\u003ctd\u003eLatest TTM vs. prior period\u003c\/td\u003e\n\u003ctd\u003eDecreased by approximately \u003cstrong\u003e13.34%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiostax Royalty Agreement\u003c\/td\u003e\n\u003ctd\u003eApril 20, 2023\u003c\/td\u003e\n\u003ctd\u003eBiostax to pay \u003cstrong\u003eroyalties\u003c\/strong\u003e to Statera for worldwide exclusive rights to LDN and MENK patents (excluding Crohn's Disease).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTivic Health License Agreement\u003c\/td\u003e\n\u003ctd\u003eFebruary 12, 2025\u003c\/td\u003e\n\u003ctd\u003eTivic acquired worldwide exclusive rights to Entolimod™ (except Crohn's Disease).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImQuest Acquisition Revenue Impact\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended December 31, 2021\u003c\/td\u003e\n\u003ctd\u003eRevenue increased \u003cstrong\u003e100%\u003c\/strong\u003e from 2020 (due to acquisition).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific examples of past and recent strategic agreements that generated or are expected to generate revenue streams include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe agreement with Tivic Health Systems for the exclusive worldwide rights to Entolimod™, a Phase III TLR5 agonist, for all indications except Crohn's Disease.\u003c\/li\u003e\n\u003cli\u003eThe Amended License Agreement with Biostax Corp., under which Biostax will pay \u003cstrong\u003eroyalties\u003c\/strong\u003e to Statera for worldwide exclusive rights to numerous patents surrounding Low-dose Naltrexone (MENK) and Met-enkephalin (MENK), with Statera retaining development and commercialization rights for Crohn's Disease.\u003c\/li\u003e\n\u003cli\u003eThe revenue structure shows high volatility, with the TTM figure of \u003cstrong\u003e$3.69 million\u003c\/strong\u003e representing a massive long-term increase of over \u003cstrong\u003e1,459%\u003c\/strong\u003e compared to the \u003cstrong\u003e$1.49 million\u003c\/strong\u003e annual revenue reported in 2021.\u003c\/li\u003e\n\u003cli\u003eThe company reported \u003cstrong\u003eno revenue\u003c\/strong\u003e in 2020.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eStatera Biopharma, Inc. (STAB) - VRIO Analysis: 9. Core Scientific Team and Institutional Knowledge\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The collective, undocumented experience in developing immunotherapies based on the AIMS platform and naltrexone\/met-enkephalin research.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. This tacit knowledge, built over years, is not on any resume.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very Low. It takes years and significant failure\/success cycles to build this level of institutional know-how.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e No. The organization is severely hampered by its financial state; retaining this team is the single biggest near-term risk.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (if retained). This is the engine for future discovery, but it’s highly vulnerable right now.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Last 12 Months\/Most Recent)\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$506,098\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.41M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$6.90 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$12.09 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash Flow Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$12.19 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash Flow Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.16\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTTM Liquidity Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.37\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTTM Liquidity Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14,517\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eValuation Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe scientific foundation and team structure are characterized by the following data points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEmployee Count: \u003cstrong\u003e16\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFounded Year: \u003cstrong\u003e2003\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePlatform Focus: AIMS platform leveraging research on naltrexone and met-enkephalin, including TLR5 agonists like Entolimod and GP532.\u003c\/li\u003e\n\u003cli\u003eClinical Programs Mentioned: Crohn's disease, hematology, pancreatic cancer, and COVID-19 mitigation.\u003c\/li\u003e\n\u003cli\u003eRecent Transaction: Tivic Health acquired exclusive worldwide rights to Phase III TLR5 agonist (Entolimod) from Statera Biopharma.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516257394837,"sku":"stab-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/stab-vrio-analysis.png?v=1740218019","url":"https:\/\/dcf-model.com\/products\/stab-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}